<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440620</url>
  </required_header>
  <id_info>
    <org_study_id>S-20140090</org_study_id>
    <nct_id>NCT02440620</nct_id>
  </id_info>
  <brief_title>Cardiac Toxicity in Medical Treatment of Breast Cancer</brief_title>
  <acronym>CaTOB</acronym>
  <official_title>Cardiac Toxicity in Medical Treatment of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will describe the epidemiology including prognosis of heart failure related to
      treatment with anthracycline and trastuzumab for breast cancer.

      In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer
      patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered
      advanced echocardiographic examination, test of bio-markers and genetic markers for the
      purpose of investigating if early identification of patients in particular risk of developing
      heart failure is feasible.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global longitudinal strain by two dimentional speckle tracking.</measure>
    <time_frame>Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio between the mitral E velocity and early diastolic maximum global strain rate (E/SRE).</measure>
    <time_frame>Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Heart Failure</condition>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be analyzed for N-terminal proBNP and ultra-sensitive TnT. Targeted
      sequencing of a limited number of well-known genes related to heart failure will be conducted
      and analysis of potential future biomarkers related to heart failure is possible from blood
      samples stored in a biobank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HER2 positive breast cancer in adjuvant treatment with trastuzumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HER2 positive breast cancer

          -  Adjuvant treatment with trastuzumab

        Exclusion Criteria:

          -  Left ventricle ejection fraction (LVEF) &lt;50%

          -  Chronic or persistent atrial fibrillation

          -  History of moderate or severe valvular heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Moeller, MD, DMsc</last_name>
    <role>Study Director</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Banke, MD</last_name>
    <phone>+45 26278303</phone>
    <email>Ann.Banke@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense c</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Banke</last_name>
      <email>Ann.Banke@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Ann Banke</investigator_full_name>
    <investigator_title>MD, Ph.d.-student</investigator_title>
  </responsible_party>
  <keyword>Heart failure related to medical treatment of breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

